Hibiskus

Hibiskus Bio is a biotechnology company focused on developing next-generation small molecule inhibitors for the treatment of solid tumors, particularly clear cell renal cell carcinoma. The company's core research centers on hypoxia-inducible factor 2-alpha (HIF-2α), a key driver in the progression of certain cancers. By utilizing advanced structural biology and medicinal chemistry, Hibiskus Bio aims to create therapies with improved potency and pharmacological properties compared to existing first-generation inhibitors. The company was founded by leading researchers from the University of Pennsylvania and is headquartered in Philadelphia's biotech hub. Their mission is to provide more effective treatment options for patients who have developed resistance to current standard-of-care therapies.